Ascendis Pharma A/S (ASND) Stock: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$227.31
-0.52 (-0.23%)
▼
5d:
-1.47%
30d:
-12.66%
90d:
-17.19%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ASND shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ASND shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$134.37
Based on -10.4% avg growth
INTRINSIC VALUE TODAY
$83.43
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $227.31, which is considered oversold relative to its 30-day fair value range of $233.46 to $263.65. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.7) compared to its historical average (30.2). Remarkably, the market is currently pricing in an annual earnings decline of 7.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is in a uptrend. Immediate support is located at $220.23, while resistance sits at $243.68.
Market Sentiment: ASND scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $309.48 (+35.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ASND is in a uptrend. Immediate support is located at $220.23, while resistance sits at $243.68.
Market Sentiment: ASND scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $309.48 (+35.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$233.46 -
$263.65
Company Quality Score
69/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (85/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.8% below Wall St target ($309.48)
- CAUTION: Bottoming setup, but lagging the sector by 27% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$233.46 -
$263.65
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$220.23
Resistance Level
$243.68
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.69
Wall Street Target
$309.48
(+35.8%)
Revenue Growth (YoY)
114.7%
Profit Margin
70.9%
Valuation Discount vs History
-7.7% cheaper
PE vs Historical
23.7 vs 30.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.7%
(market-implied from PE analysis)
1-Year Target
$210.29
(-8%)
2-Year Target
$194.09
(-15%)
3-Year Target
$179.15
(-21%)
3-Yr Target (if PE normalizes)
(PE: 24→30)
$228.36
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.7, Growth: -24.8%)
$166.09
(+-27%)
Base:
(SPY PE: 20.4, Growth: -24.8%)
$143.01
(-37%)
Bear:
(PE: 17.3, Growth: -24.8%)
$121.56
(-47%)
📈
Valuation based on Current Earnings
Trailing PE: 17.78 | Current EPS (TTM): $12.83
Bull Case
$188.03
(-18%)
Analyst growth -25.0%, PE expands to 19.6
Base Case
$170.94
(-25%)
Market implied -25.0%, PE stable at 17.8
Bear Case
$155.09
(-32%)
Severe decline -20.0%, PE contracts to 15.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.7 to 30.2
Stabilization Target:
$290.41
(+27.5%)
PE Expansion Potential:
+27.5%
Share & Embed Analysis
Last updated: October 01, 2026 4:34 PM ET
Data refreshes hourly during market hours. Next update: 5:34 PM
Data refreshes hourly during market hours. Next update: 5:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 58 HOLD |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 74 BUY |
